Raplon (rapacuronium bromide) is a surgical anesthetic used to relax skeletal muscles. The FDA authorized its usage in August 1999. As a non-depolarizing drug, it did not stimulate muscles before weakening them.
Due to the risk of deadly bronchospasm, Organon pulled it from the US market on March 27, 2001, less than two years after its FDA clearance.
Raplon has been linked to several negative side effects.
Raplon was connected to bronchospasm, a dangerous and potentially deadly complication during surgery.
Raplon clinical studies revealed that 32% of individuals suffered some adverse response, including the following:
If you or a loved one have taken the prescription medicine Raplon and have had negative side effects such as trouble breathing, wheezing, dizziness, fainting, irregular heartbeat, rash, weariness, fever, or swelling, you should talk with a lawyer right away.
Organon Inc., a subsidiary of the Netherlands-based Akzo Nobel, manufactures Raplon.
The medicine was authorized in August 1999, and the firm praised it for its “rapid onset, quick recovery time, and good side-effect profile.”
The medicine was used as a muscle relaxant in hospitals and other surgical settings, most notably while inserting a breathing tube into a patient.
Raplon was linked to many episodes of bronchospasm, an inability to breathe regularly that may result in lasting harm or death, according to the FDA.
The FDA reported over 90 cases of severe bronchospasm, including five fatalities.
It is hard to be positive that the medicine at issue is at fault, as with other “adverse outcomes” connected with a drug; other drugs or underlying disorders might also be the cause.
However, Dr. Jenkins of the FDA said that the Raplon instances were all extremely questionable since they happened close in time to the medicine administration.
The FDA and Organon anticipated occasional bronchospasm in individuals receiving the medication. Such occurrences were seen during Raplon clinical trials, are observed while taking other medications in the same class as Raplon, and are noted on Raplon’s official label.
Organon spokesperson Frances DeSena said that bronchospasms were anticipated.
Organon did not provide sales figures for the medicine but said it had been used to treat over a million people.
Raplon patients had bronchospasm 3.2% of the time in clinical trials before the medicine was authorized, compared to 2.1% for comparable treatment. This rekindled long-standing allegations that the FDA is endangering people’s lives.
Sidney Wolfe, head of Public Citizen’s Health Research Group, said Raplon was another example of a drug with proof of the same hazard that led to it being pulled off the market. She asked why Organon would put a new drug on the market if it appeared more harmful than current drugs.
A bronchial spasm, or bronchospasm, is an abrupt muscle constriction within the bronchiole walls.
Under the impact of anaphylatoxins, it is induced by the degranulation (release) of chemicals from basophils or mast cells. It causes respiratory difficulties ranging from moderate to severe.
The hyperactivity of the bronchioles’ muscle is caused by exposure to stimuli that normally elicit little or zero reaction.
The subsequent constriction and inflammation narrow the airways and increase mucus production, reducing the quantity of oxygen accessible to the person and resulting in coughing, dyspnea, and hypoxia.
Bronchospasms are a severe risk of putting in breathing tubes while a person is under anesthetics.
When the airways spasm or constrict in reaction to the irritating stimulation of the breathing tube, maintaining the airway becomes difficult, and the patient may become apneic.
High peak inspiratory pressures, increased intrinsic PEEP, wheezing, an upsloping capnograph, and reduced expiratory tidal volumes are all symptoms of bronchospasm under general anesthesia.
In extreme situations, there may be no breathing capacity, ETCO2 loss, desaturation, and hypoxia.
Furthermore, because the pediatric population’s airway diameter is smaller, they are more susceptible to complications from bronchospasm and disease; it is evident that airflow resistance through a tube is inversely related to the radius of the tube to the 4th power; thus, decreases in airway result in significant flow restrictions.
Symptoms and signs of bronchospasm include the following:
If you believe that Raplon, or any other defective medication, has had a negative impact on your life, you should speak with the doctor who gave you the prescription.
If you can’t get an answer from your doctor, seek the advice of another physician.
If you feel that Raplon or any other medication has already hurt your health, you should also talk with a dangerous medications lawyer (a lawyer who handles medical malpractice or product liability claims).
A malpractice or products liability lawyer will examine the facts of your case to establish if any negative effects on your health were the consequence of a mistake made by the doctor or other health care provider while prescribing the medicine.
You may also report adverse medication reactions to the FDA’s MedWatch program.
The MedWatch program was created to receive reports of adverse reactions, product quality issues, treatment failure, and product usage mistakes with medical items for individuals.
You should also consult with an attorney regarding reports to the MedWatch program.
It is crucial to remember that reporting adverse drug experiences to the MedWatch program may benefit the FDA’s oversight of pharmaceuticals. However, it is not a method of obtaining compensation for any harm caused by the medicine. That necessitates a lawsuit.
A drug interaction case may also be brought under product liability or defective product statutes.
A defective product is any product, such as medicine, that causes harm to a person due to incorrect labeling, a design flaw, or a manufacturing flaw.
If you experience injuries due to drug interactions, you may sue the medication maker if a faulty product causes damage.
A prominent example of a drug product defect is when the manufacturer fails to add adequate medication interaction warning labels.
If you are hurt due to a lack of warnings, there may be grounds for a personal injury claim. In an injury case, damages might cover a variety of expenditures, such as lost earnings, medical bills, and other losses.
You should speak with a skilled class action lawyer if a medication has harmed you or a family member.
You might have a claim against the doctor who gave you Raplon or healthcare personnel involved in the drug’s administration.
An experienced attorney can analyze the evidence and advise you on whether filing a lawsuit is the best course of action in your case.
Consult an experienced lawyer to get the best possible result in your Raplon case.
16 people have successfully posted their cases
